Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478364 | 1.00 | TDP1 (0.57) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL29478371 | 1.00 | TDP1 (0.57) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL29568355 | 1.00 | TDP1 (0.57) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL1927058 | 1.00 | TDP1 (0.57) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL289220 | 1.00 | TDP1 (0.57) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL1926014 | 0.98 | TDP1 (0.56) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL5329872 | 0.84 | TDP1 (0.54) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL5324786 | 0.84 | TDP1 (0.54) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL289201 | 0.84 | TDP1 (0.54) | TDP1CTNNB1CYP1A2SLC1A3SLC1A2 | |
| SCHEMBL24433733 | 0.82 | MTNR1A (0.49) | TDP1CTNNB1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | TDP1 517/4885CTNNB1 2793/4885CYP1A2 4842/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | TDP1 3651/4885CTNNB1 3421/4885CYP1A2 4872/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | TDP1 1563/4885CTNNB1 988/4885CYP1A2 3291/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | TDP1 4317/4885CTNNB1 3920/4885CYP1A2 4875/4885 |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | RNGTT, SPOUT1, NPEPPS | TDP1 802/4885CTNNB1 4838/4885CYP1A2 4883/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | TDP1 529/4885CTNNB1 3796/4885CYP1A2 4812/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | TDP1 4628/4885CTNNB1 4634/4885CYP1A2 4349/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | TDP1 517/4885CTNNB1 2793/4885CYP1A2 4842/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | TDP1 2331/4885CTNNB1 4590/4885CYP1A2 2855/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | TDP1 3651/4885CTNNB1 4227/4885CYP1A2 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.